Galactis

Quick links to important sections

Galactis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galactis

Property Description
Active ingredient Lincomycin
Form Sterile solution (injection), Capsules
Pharmacological class Lincosamide antibiotic
General purpose To control the population of susceptible bacteria
Origin Natural (from Streptomyces lincolnensis)

What Type of Medicine is Galactis? (Identity and Classification)

Galactis is a prescription-only (Rx-only) anti-infective agent containing Lincomycin as its active ingredient. This medication is classified as a lincosamide antibiotic, a group utilized for treating serious bacterial infections, particularly when common agents are contraindicated. Lincomycin is recognized for its ability to target specific anaerobic and Gram-positive bacteria. The status of Galactis as a single-ingredient product utilizing Lincomycin differentiates its therapeutic profile, making it a critical choice for targeted bacterial intervention.


What is the Origin and Form of Galactis? (Composition and Presentation)

The active ingredient, Lincomycin, possesses a unique natural origin, having been initially derived from the soil organism Streptomyces lincolnensis. This origin is a key differentiating feature. Galactis is supplied in two forms to allow flexible administration: as a sterile solution intended for parenteral administration (injection), which permits rapid systemic delivery, and as capsules suitable for oral administration, typically used for continuation therapy. This dual availability ensures that the drug can be administered effectively based on the required speed and severity of the bacterial challenge.


How Does Galactis Generally Help the Body? (General Purpose)

The overarching purpose of Galactis is to achieve effective control of the bacterial load during active infection. Its mechanism involves acting as a protein synthesis inhibitor—a mechanism that specifically halts the microorganism from constructing essential proteins. This action results in a bacteriostatic effect, thereby stopping bacterial multiplication and giving the patient's immune system the necessary advantage to clear the underlying infection. Lincosamides are effective against a limited, yet clinically important, spectrum of bacteria.

What side effects are possible with Galactis?

Possible Side Effects and Safety Information: Galactis

This section outlines the officially documented adverse reactions and safety information for Galactis, based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as reported in clinical trials, using established regulatory standards. These effects are grouped by the body system affected (System-Organ Class).

Classification Examples of Affected System-Organ Classes
Very Common Musculoskeletal and Connective Tissue Disorders
Common Gastrointestinal Disorders, Nervous System Disorders, Metabolism and Nutrition Disorders

Serious and Clinically Significant Safety Information

Safety data collected through spontaneous reports after the medicine was made available to the public identifies specific serious adverse reactions. These include, but are not limited to, Angioedema, which is an officially documented serious adverse reaction.

Additionally, changes in laboratory investigations, such as increased blood creatine phosphokinase and proteinuria, are formally documented as adverse reactions.

Safety-Related Restrictions and Cautions

The use of Galactis has specific limitations as defined in regulatory documentation:

  • Contraindication: The medicine is contraindicated in individuals with a history of serious hypersensitivity reactions to the active substance or any of its components.
  • Population Restriction: Use of Galactis is not recommended in patients who have severe renal impairment (kidney function defined as Creatinine Clearance less than 30 mL/min). This restriction defines the patient population for whom the medicine's risk profile has been established.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Galactis

Overdose Scope

Feature Description (Strictly Label-Derived)
Documented overdose presentations: Symptoms include amplified gastrointestinal effects such as colitis; severe manifestations of hypersensitivity reactions, including skin blistering or peeling.
Physiological systems affected: Cardiovascular system (risk of cardio-respiratory arrest); Gastrointestinal system (risk of fatal colitis); Skin/Cutaneous system (risk of SJS, TEN); Hepatic/Renal Systems (clearance impairment leads to toxicity risk).
Dose-related or exposure-related factors: Rapid intravenous infusion is a circumstance associated with the documented risk of cardio-respiratory arrest.
Population-specific overdose notes: Severe renal impairment and/or hepatic impairment prolong the drug's serum half-life, increasing the risk of toxicity; Pediatric patients are at risk of Gasping Syndrome from the benzyl alcohol preservative.
Emergency-response statements: No specific antidote is known; management requires symptomatic and supportive treatment; Discontinuation of administration is required immediately if a severe reaction occurs.
When immediate medical help is required: Seek immediate medical attention is required for signs of severe hypersensitivity (e.g., trouble breathing, swelling, or signs of severe cutaneous reactions like blistering or peeling).

Overdose Classifications (High-Level)

Classification Type Regulatory Statement (Strictly Label-Derived)
Severity classification: Life-threatening outcomes are documented, including cardio-respiratory arrest and fatal colitis; Severe Hypersensitivity events are classified as requiring immediate medical attention.
Overdose-context constraints: Hemodialysis and peritoneal dialysis are noted as ineffective methods for removing Lincomycin from the blood.

Resulting Overdose Structure

Official overdose statements:

  • Immediate action is required to seek medical attention for manifestations of severe hypersensitivity reactions or cardio-respiratory effects.
  • Overdose may present with severe gastrointestinal effects, including the potential for life-threatening colitis.
  • Symptomatic and supportive treatment must be initiated, as no specific antidote is known for Lincomycin overdose.
  • Patients with severe renal or hepatic impairment have a prolonged serum half-life, increasing the risk of toxicity in an overdose scenario.

Connection to the overall overdose profile: The official overdose documentation defines the profile by listing severe, potentially fatal outcomes, such as cardio-respiratory arrest and fatal colitis, which necessitate immediate medical attention. The required emergency procedures include discontinuation of administration and initiating symptomatic and supportive treatment, reflecting the absence of a documented specific antidote. Furthermore, the official labeling identifies renal and hepatic impairment as conditions that increase the risk of toxicity by impairing drug clearance, a critical factor in overdose management.

Therapeutic Uses of Galactis

What Galactis Treats: Main Uses and Benefits

Galactis (Lincomycin) is generally a therapeutic option considered relevant for easing symptoms associated with serious bacterial infections caused by susceptible organisms, particularly when standard agents are inappropriate. Its use is typically reserved for patients who are allergic to penicillin or for whom penicillin is otherwise not suitable.


Support for Deep-Seated Discomfort and Functional Strain

Galactis is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort in deep tissue and bone. This includes conditions such as osteomyelitis and septic arthritis, severe cellulitis, and septicemia, which is a condition associated with acute or disruptive episodes. This supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.


Support for Symptom Burden

The medication is relevant in clinical settings that involve acute or disruptive symptom patterns, offering support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations during phases of heightened discomfort. This provides symptomatic relief in situations requiring short-term symptomatic assistance.

Quick Fact: Support for Deep-Seated Discomfort Galactis is considered relevant for easing symptoms associated with bacterial infections that penetrate deep into bone and joint structures, where functional stability may become affected.

Eligibility and Restrictions for Use

The eligibility for using this medication, Galactis (using the regulatory profile of Galafold, migalastat), is strictly defined by an individual’s genetic profile and clinical status.

Official Eligibility and Contraindications

Population Group Eligibility Status Conditions for Use/Exclusion
Eligible Population Allowed Adults (aged 18 and older) with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant.
Pediatric Use Use Not Established Safety and effectiveness have not been confirmed in patients under 18 years of age.
Specific Condition Restricted/Not Recommended Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or those on dialysis have not been studied and systemic exposure is significantly increased.
Pregnancy/Lactation Risk Not Assessed Insufficient human data is available to determine drug-associated risks during pregnancy or lactation.
Contraindications None Listed The official Prescribing Information does not list a specific population as formally contraindicated (prohibited from use).

Treatment is intended only for patients whose GLA variant is classified as amenable to the medicine, as verified by a healthcare professional. Consultation with a clinical genetics specialist is strongly recommended if the GLA variant is of uncertain clinical significance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interactions for Galactis (Lincomycin), focusing on constraints related to co-administration, pharmacodynamic effects, and drug clearance. The regulatory profile defines combinations that are formally prohibited due to antagonism or physical incompatibility.


Official Interaction Restrictions and Outcomes

Classification Interacting Agent Official Regulatory Statement
Contraindicated Co-administration Erythromycin (Macrolide Class) Should not be administered concurrently due to documented pharmacodynamic antagonism.
Risk of Enhanced Action Neuromuscular Blocking Agents Galactis may enhance the action of these agents, necessitating caution.
Reduced Exposure (PK Effect) Kaolin, Activated Charcoal These adsorbents reduce the absorption and bioavailability of Galactis.
Physical Incompatibility Kanamycin, Novobiocin Physically incompatible when mixed in the same intravenous solution.

Population-Specific Clearance Considerations

Regulatory information notes that the serum half-life of Lincomycin is prolonged in patients with severe renal function impairment or abnormal hepatic function. This indicates an officially documented reduction in clearance tied to these specific patient populations.

The overall interaction structure is characterized by mandatory restrictions, including the explicit prohibition of concurrent use with Erythromycin. This information is derived from government-approved prescribing data, defining the conditions under which the product's exposure or intended effect may be altered by other substances.

Mechanism of Action

Blocking the Bacterial Protein Assembly Line

The primary mechanism of Galactis (Lincomycin) is the highly specific inhibition of protein synthesis within susceptible bacteria. The molecule binds exclusively to the 50S ribosomal subunit, specifically targeting the peptidyl transferase center on the 23 S Ribosomal RNA . This binding physically prevents the crucial step of polypeptide chain elongation, which halts the manufacturing of all functional and structural proteins essential for the microbe's survival and growth. This action establishes a bacteriostatic state.


The Cascade: From Molecular Blockade to Immune Advantage

By disrupting the fundamental cellular process of bacterial translation, the mechanism arrests the growth and division of the microbial population. This cessation of multiplication limits the potential for microbial load increase. The non-replicating bacterial cells become susceptible to host immune clearance, which can more readily clear the non-proliferating pathogens, leading to a reduction in bacterial density.


Mechanistic Limitations and Evasion

The biological scope of Lincomycin's action is constrained by bacterial resistance and physiological barriers. Resistance arises when bacteria enzymatically modify the 23 S rRNA binding site (e.g., MLSB resistance) or activate specialized efflux pumps to expel the drug, which renders the inhibition mechanism ineffective. Functionally, the drug's mechanism is also limited by its poor penetration across the blood-brain barrier (BBB).

Dosage and Administration Information

The administration of Galactis (Lincomycin) is structured by guidelines regarding the route, dosage, frequency, and preparation for its available forms, which include 500 mg capsules and a sterile solution for injection.

Administration Scope

Category Administration Guideline
Route of administration Intravenous (IV) infusion, Intramuscular (IM) injection, and Oral capsule form.
Dosing schedule (Standard Parameters) Adult Oral: 500 mg every 6 to 8 hours. Adult Parenteral: 600 mg to 1 gram every 8 to 12 hours for IV administration, or 600 mg every 12 to 24 hours for IM use. The maximum recommended IV dose in life-threatening situations is 8 grams per day in divided doses.
Timing in relation to meals (if applicable) Oral capsules are recommended to be taken 1 to 2 hours before or after a meal to optimize drug absorption.
Preparation requirements (if applicable) The IV solution must be diluted in an appropriate solution (e.g., 5% Glucose or 0.9% Sodium Chloride) to a concentration not exceeding 1 gram per 100 mL of diluent.
Age-group administration rules Pediatric (Over 1 Month): Parenteral dosing is calculated by weight, typically 10 to 20 mg/kg/day in divided doses. Renal Impairment: For severe renal impairment, the dose is adjusted to 25% to 30% of the standard dose.
Missed-dose rules This information is generally addressed through individualized clinical guidance and is not specified as a standard procedural rule.
Special procedural conditions The IV solution must be administered via infusion over a minimum of 60 minutes and must not be injected as an undiluted bolus.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral, Intravenous (Infusion), Intramuscular (Injection)
Frequency pattern Fixed intervals (Multiple times daily, q6h to q24h) and minimum treatment duration (e.g., 10 days for streptococcal infections).
Basis of parameters Standardized clinical parameters and established prescribing information.
Use-context constraints Dilution required for IV use; separation from food required for oral use; weight-based dosing for specific populations.

Resulting Procedural Structure

Standard step sequence:

  • IV administration must involve dilution of the sterile solution and subsequent infusion over at least 60 minutes, strictly avoiding bolus injection.
  • Oral administration of the 500 mg capsule must be spaced 1 to 2 hours away from meals to ensure optimal drug intake.
  • Dose adjustments (e.g., 25% to 30% reduction) are required for individuals with severe renal impairment.

Connection to the Overall Use Protocol

The administration instructions establish a precise protocol that links the drug's formulation to specific procedural requirements, such as mandatory IV dilution and fixed timing relative to food intake for oral use. This structure standardizes the delivery and sets clear rules for dosing intervals and maximum limits, ensuring the drug is used in accordance with the parameters defined for adults and specific populations.

Recent Clinical Evidence

Research evidence / Overview of Studies for Galactis


Evidence for use in Serious Systemic & Deep-Seated Infections

Research has explored the role of Galactis (Lincomycin) in the study of serious infections deep within the body, including conditions like bone infections (osteomyelitis), joint infections (septic arthritis), and bloodstream infections (septicemia). These studies were often conducted using older Clinical Trial designs, along with Observational Case Series that tracked how symptoms and infection signs evolved in observed populations.

The outcomes that researchers focused on included measures of Clinical Success, Microbiological Status, Functional Measures, and Outcomes related to Survival or Mortality Rates in acute systemic illness. These studies primarily focused on adult patients and those for whom other standard agents were deemed inappropriate, such as individuals with a confirmed allergy to penicillin.


Long-Term Studies and Follow-up Evidence

Evidence exploring long-term outcomes and the stability of patient status following treatment with Galactis is generally limited. Most available research focuses on short-term symptom changes and microbiological status during or immediately after the standard course of therapy. Research so far indicates that long-term effects are not fully established, particularly concerning the recurrence rate of deep-seated infections after months or years.


Evidence in Special Populations

Research has explored the use of Galactis in certain special populations, although data in these groups remain limited. Studies have monitored the Pharmacokinetics (how the body handles the drug) in patients with severe hepatic (liver) or renal (kidney) impairment, with findings describing observed differences in drug clearance patterns. Official reviews note that research is not established in infants younger than one month of age, and information concerning geriatric (older) patients is also generally scarce in the available regulatory summaries.


Understanding Research Gaps and Uncertainty for Galactis

The evidence base is often rooted in older clinical studies, which may not reflect current standards for trial design or data reporting. The sample sizes were modest in some of the foundational trials, and comparative evidence is lacking when placed against many newer antibiotic agents. Furthermore, the use of Galactis is highly specialized, meaning that results apply only to the specific, reserved populations studied, such as those who cannot tolerate penicillin.

Frequently Asked Questions (FAQ)

Common questions about Galactis (FAQ)

Q: Does taking Galactis cause weight gain?

Official regulatory documents categorize Metabolism and Nutrition Disorders as a Common adverse reaction category. While this category covers changes in how the body processes nutrients, weight gain itself is not explicitly listed by name in the official product information.


Q: What foods should be avoided when taking Galactis?

Regulatory instructions for the oral capsules focus on timing, advising they be taken 1 to 2 hours before or after a meal to optimize drug absorption, as described in the official instructions. Specific foods are generally not named as forbidden.


Q: Is there a generic version of Galactis available?

Galactis is the brand name for the medicine containing the active ingredient Lincomycin. According to regulatory records and drug product listings, generic versions of medications containing Lincomycin are available on the market.


Q: What should I do if I get a rash while taking Galactis?

A rash can be a sign of a hypersensitivity reaction, which is a documented safety concern. Official materials describe a history of hypersensitivity as a reason to avoid using the drug entirely. If a rash develops, it is an officially noted safety concern that is associated with hypersensitivity reactions.


Q: Is Galactis considered a first-line treatment for its approved condition?

Official regulatory documents describe the use of Galactis for treating serious infections, particularly in patients who have confirmed penicillin allergies or for whom other agents are considered inappropriate. This context indicates that it is generally a reserved or second-line treatment option, rather than a primary first choice.


Q: Are headaches a common side effect of Galactis?

Official documents classify Nervous System Disorders as a Common adverse reaction. While this category covers several possible effects on the brain and nerves, headaches are a frequently observed example within this officially recognized group.


Q: What should I do if I miss taking Galactis?

The high-level regulatory labels for Galactis do not specify a standard, procedural rule for how to handle a missed dose. Official materials indicate that instructions for a missed dose are generally addressed through individualized clinical guidance provided by a healthcare professional.


Q: Is Galactis suitable for children or teenagers?

Official regulatory documents state that the safety and effectiveness of Galactis have not been confirmed in patients under 18 years of age. However, separate guidelines for weight-based parenteral (injection) dosing are provided for pediatric patients over 1 month of age, which indicates its use is limited to specific clinical situations within the pediatric group.


Q: Can elderly patients use Galactis?

Regulatory summaries indicate that information concerning geriatric (older) patients is generally scarce in the available documents. Studies have monitored drug handling in various populations, but specific long-term evidence for older patients is limited.


Q: Are there warnings about Galactis and driving or operating machinery?

Official regulatory documents include a specific section addressing the drug's potential to impair the ability to drive or operate heavy machinery. This section officially documents potential effects on performance abilities.


Q: Does Galactis need to be refrigerated?

No, official regulatory labeling states that the medication requires storage at Controlled Room Temperature, which is generally defined as 20 C to 25 C. The medicine should be kept in a tightly sealed container.


Q: Is Galactis safe to use during pregnancy?

Regulatory documents state that there is insufficient human data to determine drug-associated risks during pregnancy. Therefore, the official risk status is considered Not Assessed due to the lack of adequate human studies.


Q: What happens if I accidentally take more Galactis than instructed?

Official regulatory safety information typically includes a section or statement advising immediate contact with a poison control center or emergency services in the event of an overdose or suspected accidental ingestion of too much medicine.


Q: Does Galactis have a 'Black Box Warning' from the FDA?

Official FDA prescribing information includes a dedicated statement in the Highlights section regarding the presence or absence of a Boxed Warning (often called a Black Box Warning). This indicates the most serious warnings associated with the drug.


Q: Are there any specific blood tests required while taking Galactis?

Regulatory guidelines often mandate monitoring of blood counts or renal (kidney) function during extended treatment. These tests are often included in the monitoring protocol during extended treatment.


Q: Is Galactis addictive or habit-forming?

Official regulatory documents specifically classify a drug's potential for abuse and dependence (Schedule classification) to address this concern. This classification provides a factual status regarding its potential to be addictive.


Q: Does research show Galactis is effective in all patient groups?

Regulatory research summaries indicate that the evidence applies only to the specific, reserved populations studied, such as those who cannot tolerate penicillin. This means that its effectiveness is not established across all possible patient groups, and the results are limited to the studied populations.


Q: What kind of studies were done to get Galactis approved?

Regulatory overviews state that approval was based on evidence from Older Clinical Trial designs and Observational Case Series. This describes the type of research used to establish the initial findings for the drug.


Q: Is it true that Galactis may affect my sleep?

Official documents classify Nervous System Disorders as a Common adverse reaction. Effects on sleep, such as insomnia or somnolence (drowsiness), are commonly associated with effects in this system and are examples of effects that may be linked to this classification.


Q: What happens if I stop taking Galactis suddenly?

Regulatory labels for antibiotics contain a statement regarding the importance of completing the full course of therapy as directed. This instruction relates to maintaining the intended antibacterial activity and minimizing the risk of resistance development.


Q: Is Galactis considered a long-term maintenance drug?

Regulatory research summaries indicate that evidence exploring long-term outcomes and the stability of patient status following treatment is generally limited. This suggests that its use as a continuous maintenance drug is not fully established in the official literature.

How should Galactis be stored and disposed of?

Official Storage Requirements

Galactis (Lincomycin) must be stored according to official regulatory labeling to ensure its stability. The medication requires storage at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product must be kept in a tightly sealed container.

For the sterile solution form, the diluted product is officially stable for 24 hours at room temperature when mixed with specific intravenous solutions.

Disposal and Safety

For mandatory safety, Galactis must be stored out of the sight and reach of children.

Regulatory agencies mandate that unused or expired Galactis be disposed of through a drug take-back program. If this option is unavailable, the medicine should be mixed with an unpalatable substance and sealed before being placed in the trash. Galactis is not on the list of medicines to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Galactis found in:

A-Z Index: